US · Healthcare · Biotechnology
EPS came in at 0.90 against a street estimate of 0.79 — a beat of 13.9%.
Analysts rate Biomarin Pharmaceutical Inc a buy (20 buy, 7 hold, 0 sell out of 27) with an average price target of $91.62.
CONFIDENT BioMarin posted 20% revenue growth to nearly $1B, raised full-year guidance including VOXZOGO to $1B+, and rapidly integrated Amicus with $220M annual synergies by 2028. Galafold and Pombiliti/Opfolda on track for $1.4B and $1.2B peak sales. Q2 2026 VOXZOGO ~75% revenue from OUS. Galafold in 40 countries; plan 10+ new markets. Pombiliti/Opfolda plan 20+ new markets. Analysts pressed on VOXZOGO competitive durability post-launch and exact switching guardrails (management declined to quantify forward), Amicus synergy waypoints through 2027 (half to slightly >half realized next year), and diagnosis expansion mechanics for Fabry and Pompe (country-by-country EHR, testing, genetic reclassification, family cascade programs). 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.56% |
| Dodge & Cox | 7.67% |
| PRIMECAP Management Company | 7.33% |
| Vanguard Capital Management, LLC | 4.52% |
| Vanguard Portfolio Management, LLC | 4.47% |
| NORGES BANK | 4.24% |
| State Street Corp | 4.03% |
| Viking Global Investors LP | 3.93% |
| Document | Date |
|---|---|
| Results announced · Q4 2026 HEADLINE NUMBERS • BioMarin expects approximately $283 million of pre-tax acquired in-process research and development (IPR&D) expense in Q3 2026 rel | 2026-10-06 |
| Material agreement · Q3 2026 HEADLINE NUMBERS • On September 24, 2026, BioMarin entered into a Settlement and License Agreement with Ascendis Pharma A/S. • Ascendis will pay Bio | 2026-09-30 |
| Company announcement · Q3 2026 BIOMARIN PHARMACEUTICAL INC. - DOCUMENT SUMMARY HEADLINE NUMBERS • Company: BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) • Announcement Date: Septemb | 2026-09-15 |
| Board / officer change · Q3 2026 BIOMARIN PHARMACEUTICAL INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 10 to 11 members on September 10, 2026 • Robert Plenge, | 2026-09-14 |
| Company announcement · Q3 2026 BIOMARIN PHARMACEUTICAL INC. - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • BioMarin Pharmaceutical Inc. completed the acquisition of Alesta Therapeu | 2026-09-01 |
| Material agreement · Q3 2026 BIOMARIN PHARMACEUTICAL INC. - 8-K SUMMARY HEADLINE NUMBERS • BioMarin entered into a binding term sheet with Ascendis Pharma A/S on August 30, 2026 | 2026-08-31 |
| Material agreement · Q3 2026 BIOMARIN PHARMACEUTICAL INC. – 8-K SUMMARY HEADLINE NUMBERS • BioMarin acquiring Alesta Therapeutics B.V. for $275 million upfront cash payment (on | 2026-08-18 |
| Quarterly report · Q2 2026 BIOMARIN PHARMACEUTICAL INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product revenues Q2 2026: $984.4 million (vs. $813.0 million Q2 2025) – u | 2026-08-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Preliminary financial impact disclosed; updated full-year guidance expected with third-quarter results BioMarin completed its acquisition of Alesta Therapeutics on August 31, 2026. The company expects the deal to create approximately $283 million in pre-tax acquired in-process research and de | 2026-10-06 |
| Settlement and license agreement granted for CNP therapeutic patents BioMarin Pharmaceutical settled a patent dispute with Ascendis Pharma by granting them a license to develop and sell TransCon CNP (navepegritide/Yuviwel), a C-type natriuretic peptide treatm | 2026-09-30 |
| Entered into Share Purchase Agreement for acquisition transaction BioMarin Pharmaceutical completed its acquisition of Alesta Therapeutics on August 31, 2026. This deal was previously announced on August 18, 2026 via an earlier 8-K filing. BioMarin acquire | 2026-09-01 |
| Entry into term sheet with Ascendis for settlement and license agreement BioMarin Pharmaceutical announced it has entered into a Term Sheet with Ascendis regarding a settlement and license agreement. The company plans to resolve pending legal proceedings between | 2026-08-31 |
| Acquisition of Alesta Therapeutics by BioMarin Pharmaceutical announced BioMarin Pharmaceutical announced it is acquiring Alesta Therapeutics B.V. through a Share Purchase Agreement dated August 17, 2026. The 8-K filing primarily contains standard regulatory dis | 2026-08-18 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Biomarin Pharmaceutical Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.